Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes by Wei, Datsen G. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 2, July 18, 2005 239–248 www.jem.org/cgi/doi/10.1084/jem.20050413
 
ARTICLE
 
239
 
Expansion and long-range differentiation 
of the NKT cell lineage in mice expressing 
CD1d exclusively on cortical thymocytes
 
Datsen G. Wei,
 
1,2 
 
 Hyunji Lee,
 
3
 
 Se-Ho Park,
 
3
 
 Lucie Beaudoin,
 
4
 
 Luc Teyton,
 
5
 
 
 
Agnès Lehuen,
 
4
 
 and Albert Bendelac
 
1
 
1
 
Committee on Immunology, University of Chicago, Chicago, IL 60637
 
2
 
Department of Molecular Biology, Princeton University, Princeton, NJ 08544
 
3
 
School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, South Korea
 
4
 
Institut National de la Santé et de la Recherche Médicale U561, Hospital Cochin-Saint Vincent de Paul, 75014, Paris, France
 
5
 
Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037
 
Unlike conventional major histocompatibility complex–restricted T cells, V
 
 
 
14-J
 
 
 
18 
NKT cell lineage precursors engage in cognate interactions with CD1d-expressing bone 
marrow–derived cells that are both necessary and sufficient for their thymic selection 
and differentiation, but the nature and sequence of these interactions remain partially 
understood. After positive selection mediated by CD1d-expressing cortical thymocytes, 
the mature NKT cell lineage undergoes a series of changes suggesting antigen priming 
by a professional antigen-presenting cell, including extensive cell division, acquisition 
of a memory phenotype, the ability to produce interleukin-4 and interferon-
 
 
 
, and the 
expression of a panoply of NK receptors. By using a combined transgenic and chimeric 
approach to restrict CD1d expression to cortical thymocytes and to prevent expression on 
other hematopoietic cell types such as dendritic cells, macrophages, or B cells, we found 
that, to a large extent, expansion and differentiation events could be imparted by a single-
cognate interaction with CD1d-expressing cortical thymocytes. These surprising findings 
suggest that, unlike thymic epithelial cells, cortical thymocytes can provide unexpected, cell 
type–specific signals leading to lineage expansion and NKT cell differentiation.
 
CD1d-restricted mouse V
 
 
 
14-J
 
 
 
18/V
 
 
 
8 and
human V
 
 
 
24-J
 
 
 
18/V
 
 
 
11 NKT cells are innate-
like autoreactive lymphocytes that regulate a
number of infectious, autoimmune, and cancer-
ous conditions (1–3). Their development differs
strikingly from that of conventional MHC-
restricted CD4 and CD8 T cells. Although the
thymic precursors to both NKT cells and con-
ventional T cells require interaction with their
respective self ligands in the cortex for posi-
tive selection, the mature heat stable antigen
(HSA)
 
low
 
 NKT cells subsequently undergo a
complex series of activation and differentiation
events. These events include multiple rounds
of cell division leading to massive lineage ex-
pansion and acquisition of the CD44
 
high
 
 memory
phenotype before migration to the periphery,
sequential activation of the IL-4 and IFN-
 
 
 
gene loci, and expression of NK lineage markers
such as NK1.1, NKG2D, Ly49, and CD94/
NKG2 over the course of several weeks (4, 5).
Because the NKT cell fate is imparted by the
V
 
 
 
14-J
 
 
 
18/V
 
 
 
8 TCR (6), it is believed that
differential signaling induces the sequential
changes leading to full NKT cell differentia-
tion. Indeed, rather than the antagonist/partial
agonist ligands that select conventional T cells,
an agonist self-glycosphingolipid, iGb3, is rec-
ognized by mouse and human NKT cells (7).
Expression of dominant negative forms of Ras
and Mek1, although abolishing conventional
T cell development, does not impair NKT
cells (8). Conversely, Fyn (9, 10) and NF-
 
 
 
B
(11–13) are specifically required for NKT cells
but not for conventional T cells. Finally, BM
chimera experiments have demonstrated that,
in contrast with MHC for conventional T cells,
expression of CD1d on the BM-derived rather
than epithelial cell compartments is necessary
and sufficient for NKT cell development (14–
17). These radical differences have suggested a
model whereby agonist ligand signaling in
conjunction with uncharacterized accessory
signals emanating from BM-derived cell types
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direct NKT cell positive selection and subsequent expansion,
differentiation, and survival. Like the NK cell, the final
NKT cell product balances TCR autoreactivity with inhibi-
tory signaling by NK receptors (18–20).
The BM-derived cell types involved in NKT cell devel-
opment have not been directly identified. However, the au-
toreactivity of NKT cells and the orchestrated series of
changes associated with their passage through different com-
partments of the thymus and periphery have suggested that
sequential TCR interactions with a variety of CD1d-express-
ing cells continue to drive their differentiation. In particular,
it is thought that the massive expansion initiated after positive
selection, at the HSA
 
low
 
CD44
 
low
 
 stage, would require inter-
action with professional APCs in the medulla (4, 21); that the
sequential expression of inhibitory NK receptors over several
weeks might also require TCR signaling to select appropriate
inhibitory receptors that quench TCR autoreactivity (17, 19,
20, 22); and, although CD1d is not required for survival of
terminally differentiated NKT cells (23), that the effector sta-
tus of NKT cells suggested by their explosive cytokine release
upon TCR stimulation (24) and their basal low-level tran-
scription of cytokine genes (25) must be maintained by re-
peated TCR engagement. Mixed BM chimeras using 
 
 
 
2
 
 mi-
croglobulin
 
 KO BM cells as NKT cell precursors and T cell
developmental stage mutant BM cells as CD1d/APCs have
revealed a requirement for a cell type present in 
 
TCR
 
 
 
- but
not 
 
TCR
 
 
 
-deficient thymus, most likely the double-positive
(DP) cortical thymocytes (17). Consistent with this finding,
DP thymocytes highly express CD1d, and they directly stim-
ulate autoreactive V
 
 
 
14
 
 
 
 NKT cell hybridomas (26). How-
ever, these chimeras still harbored many other CD1d-express-
ing cell types, such as DCs, B cells, and macrophages, whose
contribution could not be tested. Thus, the issue as to which
of these other cell types would control different aspects of
NKT cell differentiation, particularly those happening days or
weeks after emigration from the cortex into the medulla and
into the periphery, has remained unanswered.
CD1d is ubiquitously expressed in the thymus and found
in cortical and medullary epithelial cells, macrophages, and
DCs, but also is conspicuously expressed at high levels in DP
cortical thymocytes and at lower levels on mature T cells
(27). Recent experiments have shown that mice expressing
CD1d under the control of an MHC class I or MHC class II
promoter failed to support NKT cell development, consis-
tent with a requirement of CD1d expression by cortical thy-
mocytes (27, 28). Here, we generated transgenic and chi-
meric mutant mice expressing CD1d under the proximal 
 
Lck
 
promoter to test directly the contribution of the expression
of CD1d on cortical thymocytes to NKT cell development.
Surprisingly, our results indicate that CD1d expression on
cortical thymocytes is not only required but is, in fact, suffi-
cient to induce massive lineage expansion and distinct differ-
entiation and survival events long after emigration from the
cortex into the medulla and the periphery. Other peripheral
CD1d-expressing cell types, although not essential, seemed
to enhance the differentiation process leading up to NK dif-
ferentiation; this observation suggests some functional influ-
ences of prolonged TCR interactions.
Figure 1. CD1d expression and NKT cells in pLck-CD1d mice. 
(A) Transgenic construct for expression of CD1d cDNA under the control 
of the proximal Lck promoter. CD1d cDNA was inserted via the EcoRI site 
located in the second exon of the  -globin expression cassette. Black boxes, 
exons; thin lines, introns; gray box, promoter. The construct was excised via 
SpeI and XhoI sites from the bacterial vector, purified, and injected into 
fertilized eggs. (B) CD1d (red) versus I-Ab (green) expression in frozen thymic 
sections of three different lines of pLck-CD1d mice, pLck/low, pLck/high, and 
pLck/var, compared with CD1d Het (CD1d / ) and CD1d KO (CD1d / ) litter-
mate controls. Upper four rows are mice in the NODxC57BL/6 F1 back-
ground; bottom two rows are in the C57BL/6 background. A thin white line 
delineates the boundary between cortex (c) and medulla (m). Note the varie-
gated pattern of CD1d expression in pLck/var. (C) Staining of total thy-
mocytes and splenocytes with CD1d tetramers loaded with  -GalCer (L-Tet, 
y-axis) versus anti-B220   unloaded CD1d tetramers (UL-Tet   B220, 
x-axis). Percentages of NKT cells   SD, compiled from five experiments and 
five to eight mice per line, are shown in upper left quadrants. 
JEM VOL. 202, July 18, 2005
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RESULTS
 
pLck-CD1d
 
 mice
 
To restrict CD1d expression on the T cell lineage, we con-
structed transgenic vector using the proximal 
 
Lck
 
 promoter
(29) to drive CD1d cDNA in a 
 
 
 
-globin expression cassette
(Fig. 1 A). Five founders were established by injection into
fertilized oocytes of inbred B6 (
 
n
 
 
 
 
 
 2) or nonobese diabetic
(NOD) strains (
 
n
 
 
 
 
 
 3). The B6 founders subsequently were
bred to the B6.
 
CD1d 
 
KO background, and the NOD
founders were bred to NOD.
 
CD1d 
 
KO mice followed by a
cross to B6.
 
CD1d 
 
KO mice to obtain (NODxB6) F1.
 
CD1d
 
KO mice. The transgenic lines in the 
 
CD1d
 
 homozygous
KO background are thereafter termed 
 
pLck-CD1d
 
 mice. For
in-depth analysis of CD1d expression, we selected a 
 
pLck/
low
 
 and a 
 
pLck/high
 
 as low and high expressors, respectively,
as well as a 
 
pLck/var
 
 exhibiting a variegated pattern of ex-
pression on 
 
 
 
10–20% of thymocytes. All 
 
pLck-CD1d
 
 lines
showed faithful expression of CD1d in the T cell lineage,
i.e., cortical thymocytes and mature T cells. Examples of ex-
pression pattern in 
 
pLck-CD1d
 
 mice are shown in Fig. 1 B
and Fig. 2 and are summarized in Table I. Our breeding
scheme allowed each transgenic mouse to be analyzed side
by side with a nontransgenic 
 
CD1d
 
 
 
/
 
 
 
 (
 
CD1d Het
 
) litter-
mate for optimal comparison purposes.
In thymic frozen sections (Fig. 1 B), 
 
CD1d Het
 
 controls
showed broad expression of CD1d (red) not only on all cor-
tical thymocytes, but also on all MHC class II I-A
 
b
 
 
 
 cells
(green), including cortical and medullary epithelial cells,
CD11c
 
 
 
 DCs, and CD11b
 
 
 
 macrophages, as previously
shown (27). In contrast, 
 
pLck/low
 
, 
 
pLck/high
 
, and 
 
pLck/var
 
expressed CD1d on cortical and, to a lesser extent, medul-
lary thymocytes, but not on any I-A
 
b
 
 
 
 cells.
A more quantitative assessment of CD1d expression by
different cell types was performed using flow cytometry
(summarized in Table I for 
 
pLck/low
 
 and 
 
pLck/high
 
 and
shown in Fig. 2 for 
 
pLck/var
 
). Although CD1d expression
was restricted absolutely to the T cell lineage, both in the
thymus and periphery, the level of CD1d expression varied
in different transgenic lines, ranging from five to 20 times
the level expressed by 
 
CD1d
 
 
 
/
 
 
 
 heterozygous controls, i.e.,
2.5 to 10 times the levels of WT 
 
CD1d
 
 
 
/
 
 
 
. The 
 
pLck-CD1d
 
transgenic mice exhibited a marked drop in CD1d expres-
Figure 2. Pattern of CD1d expression in pLck/var mice. CD1d 
expression on gated thymic (left column) and peripheral (right column) 
subsets shown in green for WT, red for pLck/var, and black for CD1d KO. 
Percentages and mean fluorescence intensity of CD1d  cells are indi-
cated above fluorescence peaks. Results are representative of three 
independent experiments, and more than three mice are analyzed for 
each cell type. (left) DN, CD4 8  DN and CD3  ; DP, CD4 8 . CD4 and 
CD8 are mature HSAlow single-positive cells. NKT are NK1.1 CD3   cells. 
Thymic dendritic cells (DC) were enriched with anti-CD11c magnetic 
microbeads and further gated on CD11c I-Ab  for analysis. Thymic 
macrophages (M ) were enriched and gated similarly with CD11b; 
thymic epithelial cells (TEC) were enriched by depleting hematopoietic 
cells with anti-CD45 magnetic microbeads, and gating on CD45-I-Ab  
cells. (right) BM, CD3   BM cells. All other subsets are gated from 
splenic preparations, except PMN, Gr-1 CD3   polymorphonuclears 
from peripheral blood.
Table I.  CD1d expression levels in splenic and thymic subsets 
of pLck-CD1d mice
Thymus Spleen
Mice DN DP CD4 CD8 CD4 CD8 B DC M 
CD1d Het 182 125 109 82 97 74 178 129 79
CD1d KO 12 17 15 13 19 8 8 5 5
pLck/low 437 563 87 57 78 60 5 4 7
pLck/high 3,476 3,038 1,384 1,197 1,154 918 8 5 8
Mean fluorescence intensity is shown, averaged from three independent analyses of 
one or two mice per transgenic line.NKT CELL DIFFERENTIATION IN PLCK-CD1D TRANSGENIC MICE | Wei et al. 242
sion between the immature cortical DP and the single-posi-
tive mature T cell stage, as expected.
NKT cell selection, expansion, and differentiation in 
pLck-CD1d mice
Next, we examined the NKT cell developmental stages in
the  pLck-CD1d mice using flow cytometry with various
stage-specific markers and  -galactosylceramide ( -Gal-
Cer)–loaded CD1d tetramers specific for the canonical
V 14-J 18 TCR. Remarkably, all lines of pLck-CD1d mice
expressed substantial percentages of NKT cells (Fig. 1 C).
Despite their reduced proportion of DP thymocytes express-
ing CD1d, the pLck/var mice (C57BL/6 background) ex-
pressed the same frequencies and absolute numbers of NKT
Figure 3. NKT cell phenotype in pLck/var mice. (A) TCR V  repertoire 
analysis on gated CD3  CD1d- -GalCer tetramer  NKT cells and main-
stream CD3   T cells in the spleen of pLck/var and CD1d Het littermate 
controls, as indicated. Results shown as mean   SD of data collected from 
nine mice in two independent experiments. (B) CD44/NK1.1 and CD4/CD8  
staining of NKT cells in thymus, spleen, and liver of pLck/var mice and CD1d 
Het controls. Percentages and SD from 23 mice in seven experiments are 
indicated. *, P   0.05 by unpaired Student’s t test. (C) Analysis of NK and 
activation/memory markers expressed by gated CD1d- -GalCer tetramer  
NKT cells of pLck/var (red) versus littermate CD1d Het control (green). Results 
representative of six pairs of pLck/var transgenic and WT littermates. 
Similar results were found for pLck/low mice (data not depicted).JEM VOL. 202, July 18, 2005 243
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cells in the thymus and spleen as CD1d /  littermate con-
trols at the adult age (Fig. 1 C) as well at the younger ages of
2 and 4 wk (unpublished data). In the C57BL/6 back-
ground, CD1d /  and CD1d /  mice have the same num-
ber of NKT cells (unpublished data). The pLck/low and
pLck/high mice (NODxC57BL/6 F1) expressed 1.5 to three
times more NKT cells than CD1d /  controls (Fig. 1 C), or
about the same as CD1d /  mice in the NODxC57BL/6
background (unpublished data). Similar results were found
for liver lymphocyte samples (unpublished data).
NKT cells in pLck/var mice expressed the same V  reper-
toire composed of three families, V 8 V 7 V 2 (Fig. 3
A), and passed through the same CD44low, CD44high, and
NK1.1  stages as WT mice with no difference in their dou-
ble-negative (DN)/CD4 ratio (Fig. 3 B). However, one con-
sistent defect observed in the three pLck-CD1d transgenic
lines examined was an  30% lower ratio of NK1.1 /
NK1.1  cells in peripheral tissues (spleen and liver) (Fig. 3 B
and unpublished data). These mature NK1.1  cells, however,
expressed the whole complement of NK lineage receptors
examined, with intensity and frequency similar to those seen
in WT mice (Fig. 3 C), including NKG2D, Ly49A, C/I, G2,
CD94, NKG2A/C/E, and other characteristic markers such
as DX5, CD44, CD62L, CD69, and CD122.
We next measured the rate of cell divisions previously
reported at the HSAlowNK1.1  stage of NKT cell thymic
development. 4 hr after an i.p. injection of 1 mg bromode-
oxyuridine (BrdU), 11–12% of NK1.1  thymic NKT cells
were labeled in WT, as in pLck/var mice (Fig. 4), demon-
strating that the massive lineage expansion that is a hallmark
of this NKT cell thymic stage occurred normally.
Cell-intrinsic expression of CD1d enhances positive selection 
of NKT cell precursors
Further analysis of pLck/var mice with a variegated pattern of
transgene expression provided an unexpected clue to the ongo-
ing interactions between the NKT cell precursors and CD1d-
expressing cells. We made the surprising observation that the
frequency of CD1d expression among positively selected
HSAlowCD44low NKT cells (40.1%) was two times higher than
expected from the frequency among DP thymocytes (18.6%)
(Fig. 5 A). This increased frequency was particularly evident at
the early HSAlowCD44low NKT cell stage after positive selection
from the HSAhigh stage, when pLck-driven CD1d expression is
not yet extinguished. This surprising but consistent result might
suggest that developing NKT cells use their own CD1d to
enhance positive selection. To evaluate further the general
significance of this unexpected result, we generated mixed
WT   CD1d KO into CD1d KO radiation BM chimeras in
which CD1d expression was confined to a fraction of thy-
mocytes. Here again, the proportion of NKT cells expressing
CD1d was approximately twice that of DP or mainstream T
cells (Fig. 5 B). Thus, the data suggest that, although not essen-
tial, intrinsic expression of CD1d significantly enhances the se-
lection and development of NKT cell precursors.
CD1d-expressing DP thymocytes are sufficient for positive 
selection of NKT cells
Although the quasinormal selection, differentiation, and mat-
uration of NKT cells in pLck-CD1d mice rules out an essen-
Figure 4. BrdU incorporation by NKT cell subsets in vivo. 4 h after 
i.v. injection of BrdU, pLck/var and control CD1d Het showed similar fre-
quency of BrdU  cells among CD1d- -GalCer tetramer  NKT cell subsets. 
Similar results were found in three different experiments. Percentages of 
BrdU  cells are shown in top right quadrants.
Figure 5. CD1d expression autonomously enhances NKT cell devel-
opment. (A) Frequency of CD1d expression is higher among NKT cells of 
pLck/var mice than among total thymocytes. The difference is particularly 
visible at the CD44low NKT stage before extinction of the pLck promoter. 
Frequencies are indicated as mean   SD of three mice. (B) In mixed WT   
CD1d KO BM radiation chimeras, a higher proportion of NKT cells are CD1d-
positive than expected from analysis of the DP and conventional mature 
CD4 and CD8 T cells. Data are representative of three individual chimeras.NKT CELL DIFFERENTIATION IN PLCK-CD1D TRANSGENIC MICE | Wei et al. 244
tial contribution by DCs, macrophages, or thymic epithelial
cells, it was important to investigate whether transgenic ex-
pression of CD1d on mature T cells inside and outside the
thymus was contributing to NKT cell development. Indeed,
even though the proximal Lck promoter is substantially extin-
guished after the DP stage, residual gene expression com-
bined with the long lifespan of CD1d proteins provides a
window of opportunity for mature HSAlow NKT thymocytes
to interact with CD1d (including CD1d expressed on NKT
cells themselves, as described before) after they exit the cor-
tex. Such interaction might account for the rounds of cell di-
vision and the effector/memory formation that characterize
this developmental stage, as well as terminal NK differentia-
tion in the periphery. To abrogate this residual expression of
CD1d in the thymic medulla and in the periphery, we gener-
ated mixed BM radiation chimeras using a mixture of pLck/
low.C  KO BM (as antigen-presenting component, unable to
generate T cells) and CD1d KO BM (as responding compo-
nent, generating the T cell but unable to present antigen).
The hosts were irradiated CD1d KO mice. In these chimeras,
therefore, CD1d was expressed only on cortical thymocytes
that were themselves unable to mature because of the C 
mutation, whereas NKT cells could only arise from cells that
were themselves CD1d KO. Surprisingly, NKT cells were
quasinormally generated in such chimeras by comparison
with control CD1d KO   C  KO mixed chimeras (Fig. 6).
NKT cells were identical to controls in terms of num-
bers, V  repertoire, and DN/CD4 ratio, as well as pattern of
NK receptor expression (unpublished data), although the
proportion of NK-lineage receptor-expressing cells was sub-
stantially decreased in the periphery (Fig. 6). Similar results
were observed using pLck/var.C  KO cells instead of pLck/
low.C  KO BM cells (unpublished data). Thus, these mixed
chimeras firmly establish that, even with CD1d expression
strictly confined to the thymic cortex, NKT cell develop-
ment proceeds through the sequential stages leading to the
final NKT cell product weeks after emigration to the pe-
riphery. The partial defect in peripheral NK1.1 acquisition
previously noted in the pLck-CD1d mice as compared with
WT mice was observed again when compared with control
chimeras. In fact, in these mixed chimeras, the relative defect
tended to be even more severe (50% reduction) than when
pLck-CD1d mice were compared with WT littermates (30%
reduction), possibly because of the more restricted distribu-
tion of CD1d expression.
NKT cell responses in pLck-CD1d mice
To study the functional properties of NKT cells developing
in pLck-CD1d mice, in which CD1d expression by periph-
eral APCs is absent, we first injected DCs loaded with the
agonist NKT cell ligand  -GalCer intravenously and mea-
sured cytokines released in the sera. Peak IFN-  secretion
not only was preserved but was, in fact, consistently three to
four times higher in the two pLck-CD1d lines examined,
pLck/var and pLck/low, than in WT cells (Fig. 7 A). IL-4 was
not detected in this assay. However, the early IL-4 release
induced by anti-CD3  i.v. injection, a characteristic func-
tional property of effector-stage NKT cells (24), was unim-
paired and perhaps was increased slightly in pLck/var mice
compared with CD1d Het littermate controls (Fig. 7 B). In
an in vitro assay combining sorted splenic CD1d- -GalCer
tetramer NK1.1  NKT cells and  -GalCer-pulsed DCs,
NKT cells from pLck-CD1d mice secreted both IFN-  and
IL-4, again significantly more than WT cells (Fig. 7 C).
Figure 6. NKT cell development in CD1d KO   pLck/low.C  KO 
mixed BM chimeras. Irradiated (900 rad) C57BL/6.CD1d KO recipients 
of a mixture of BM cells, as indicated, were analyzed for frequency and 
phenotype of CD1d- -GalCer tetramer  NKT cells 6–8 wk after reconsti-
tution. In these experiments, the pLck/low.C  KO BM cells were obtained 
from a H-2b donor. Percentages   SD are calculated from four individual 
chimeras. *, statistically significant differences (P   0.05, unpaired Student’s 
t test). The bottom table recapitulates the thymic and peripheral cell types 
expressing ( ) or not expressing ( ) CD1d in these chimeras.JEM VOL. 202, July 18, 2005 245
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We next crossed the pLck/var mouse with the E -
CD1d transgenic mouse, which expresses CD1d exclusively
under the control of the MHC class II E  promoter. The
E -CD1d transgenic mouse previously was shown to ex-
press CD1d faithfully according to the MHC class II pat-
tern, i.e., in the thymic epithelium as well as in thymus and
peripheral APCs, including DCs, macrophages, and B cells
(27). Together, the pLck and E  promoters reconstitute the
natural distribution of CD1d (with the exception of hepa-
tocytes). Strikingly, the splenic NKT cell responses in these
double-pLck/var.E -CD1d transgenic mice were normal-
ized, comparable to WT B6 mice (Fig. 7 C). In addition,
the relative defect in the acquisition of NK receptors by pe-
ripheral NKT cells was corrected (Fig. 7 D), demonstrating
the concomitant influence of peripheral CD1d-expressing
APCs in promoting the terminal differentiation. Similar
findings were observed when the pLck/var mice were
crossed with WT mice (Fig. 7, C and D), further demon-
strating that the altered tissue expression pattern of CD1d,
restricted to T cells, accounted for the relative decrease in
terminal NKT cell differentiation and concomitant increase
in cytokine secretion.
DISCUSSION
In an attempt to account for the complex, orchestrated se-
quence of thymic and peripheral events leading to the natural
NKT cell differentiation in response to self-agonist self
ligands such as iGb3, this study focused on elucidating the na-
ture of the CD1d-expressing cell types involved at different
stages of the process, from positive selection in the thymic
cortex to clonal expansion and cytokine gene locus activation
in the medulla and to the unique expression of the NK pro-
gram in the periphery. Previous studies had indicated that the
entire sequence of events could be directed by CD1d-express-
ing BM-derived cells (14–17), that CD1d-expressing DP
thymocytes were required for the process (17), and that DCs
transgenically overexpressing CD1d could induce negative
selection (21). Thus, although the survival of terminally dif-
ferentiated NKT cells was shown to be independent of CD1d
(23), it was logically anticipated that the different stages of
NKT cell development and differentiation occurring after
positive selection and leading to the terminal NKT cell stage
would require additional interactions between the NKT cell,
autoreactive TCR, and agonist iGb3 or other ligands in dif-
ferent cell types of the thymus and periphery.
Figure 7. Cytokine secretion by NKT cells in vivo and in vitro. 
(A) Mice of indicated genotypes were injected i.v. with 5   105  -Gal-
Cer-pulsed DCs ( GC-DC), and IFN-  was measured in sera taken at 
indicated time points. Results are shown as mean   SD of two indepen-
dent experiments, each including four mice per group. (B) Early IL-4 
released in vitro by cultured  1-mm3 splenic fragments, 90 min after i.v. 
injection of 1.25  g anti-CD3  in vivo. (C) Titrated numbers of sorted 
CD1d- -GalCer tetramer NK1.1  cells were stimulated with 105  -Gal-
Cer-pulsed DCs, before collection of supernatant for cytokine assays 
48 h later. Results pooled from at least three independent experiments. 
Error bars represent 1 SD (not all error bars are visible). (D) CD44/NK1.1 
staining of splenic CD1d- -GalCer tetramer  NKT cells in age-matched 
(6 wk) mice of indicated genotypes. Percentages and SD from three mice 
per group in three independent experiments are indicated. *, statistical 
significance by unpaired Student’s t test.NKT CELL DIFFERENTIATION IN PLCK-CD1D TRANSGENIC MICE | Wei et al. 246
The present findings, however, clearly establish that, to a
large extent, a single, temporo-spatially restricted TCR in-
teraction between the immature V 14  T cell precursor and
CD1d-expressing DP T cells in the thymic cortex is suffi-
cient to induce the whole sequence of distinct events that
characterize NKT cell differentiation, even weeks after im-
migration to the periphery. Careful analysis by flow cytome-
try and tissue immunohistochemistry of the pattern of CD1d
expression in the pLck-CD1d transgenic mice excluded cryp-
tic or aberrant expression of CD1d. Furthermore, because
analysis of the pLck/var mouse demonstrated that expression
of CD1d by the developing NKT cell itself could have a
substantial impact on its differentiation, we generated mixed
chimeras in which we could observe the development of
CD1d KO thymocytes in response to pLck-CD1d BM cells
developmentally arrested at the DP stage. In this experimen-
tal set up, in which CD1d could be presented only in trans
by cortical thymocytes, NKT cells were selected, amplified,
and differentiated largely as in WT. Thus, we conclude that
the transient interaction of the immature V 14  thymocyte
with CD1d expressed by neighboring cortical thymocytes is
sufficient to switch on the long-range expansion and differ-
entiation program that characterizes the NKT cell lineage. 
This conclusion is surprising for several reasons. First,
TCR engagement in the cortex has not been shown previ-
ously to induce entry into cell cycle, nor do DP thymocytes
express the B7 costimulatory molecules normally required to
induce naive T cell expansion. Second, because CD1d ex-
pression was largely extinguished in the periphery of pLck-
CD1d mice and completely absent in the mixed chimeras,
how did NKT cells, unlike other T cells (30), survive and
maintain an effector status in the absence of TCR signals?
Perhaps the induction of a memory phenotype and expres-
sion of the IL-15 receptor CD122 chain in the thymus, be-
fore emigration, constitutes the solution to this enigma, be-
cause memory cells expressing IL-15 receptor are largely
independent of TCR engagement for survival (23). Third, if
NK receptors serve the purpose of balancing TCR autoreac-
tivity (18), how could they be selected in the absence of
TCR signals? Our findings indicate that the genetic program
of NK lineage differentiation, although it unfolds after emi-
gration to the periphery, is activated in the thymus. Al-
though we found no changes in the expression of the indi-
vidual NK receptors examined, others may be altered, and it
is possible that more NKT cells have mismatched NK recep-
tors in pLck-CD1d mice than in WT mice, explaining their
greater responses to TCR stimuli. This greater mismatch
might explain the tendency of NKT cells from pLck-CD1d
mice to exhibit higher TCR reactivity than their WT coun-
terparts, an appealing possibility that could not be tested in
this transgenic system. Alternatively, inhibitory receptors
may selected based on their ability to antagonize activating
NK receptors such as NK1.1 and NKG2D. This plasticity in
the developmental scheme may also reflect plasticity in func-
tional activation, because evidence suggests that NKT cells
can suppress type I diabetes in a CD1d-independent manner
(unpublished data).
Interestingly, although the transition to the NK stage was
preserved in the pLck-CD1d mice, it seemed to be somewhat
less efficient than in WT mice. This observation was con-
firmed further in the mixed BM chimeras, an experimental
system in which CD1d could be restricted to a subset of de-
velopmentally arrested C  KO thymocytes. Together with
the higher reactivity of NKT cells in these mice, these obser-
vations suggest that, in WT mice, additional interactions
with other types of CD1d-expressing cells may shape further
some of their functional properties and terminal differentia-
tion. Although one cannot rule out the possibility that these
changes might be related in part to the transgenic system,
our results indicated that both the hyperreactivity and the
delayed NK receptor expression were corrected after intro-
duction of the E -CD1d transgene (driving CD1d with an
MHC class II promoter) or the WT CD1d in these pLck-
CD1d mice. These findings support the notion that addi-
tional interactions with CD1d-expressing APCs fine-tune
NKT cell development and function. The mechanisms in-
volved in these tuning events remain to be elucidated.
Agonist-driven thymocyte development has been re-
ported in a number of transgenic systems (31–37), resulting
in altered differentiation programs leading to the NKT cell,
CD4 CD25 , or CD8   lineages with various memory/ef-
fector phenotypes. Although both the epithelial and the BM-
derived compartments of the thymus could support the dif-
ferentiation of such autoreactive cells, the specific nature of
the signaling events involved has remained elusive. The cru-
cial role of Fyn in V 14  NKT cell development (9, 10) is
particularly intriguing in light of the recent discovery of its
upstream connections to signaling lymphocytic activation
molecule (SLAM)–associated protein (SAP) and SLAM-type
molecules and downstream activation of NF- B (38, 39). In-
deed, NF- B mutant mice exhibit major NKT cell develop-
mental defects (11–13), and we have found that SAP-defi-
cient mice, like Fyn KO mice, also completely lacked NKT
cells (unpublished data). SLAM-type molecules and SAP are
prominently expressed by cortical thymocytes (40), suggest-
ing that homophilic interactions between SLAM family
members expressed by developing V 14  T cells and their
fellow CD1d-expressing DP thymocytes might be essential
to NKT cell development and differentiation, providing the
costimulation needed for expansion and perhaps also for res-
cue from negative selection. It is striking that, unlike CD1d
molecules, MHC class I molecules are transiently down-reg-
ulated during the DP stage, both in mouse and human (41).
It is intriguing, therefore, to speculate that these conspicuous
differences underlie fundamentally different pathways of T
cell development for the recognition of different categories
of antigens, i.e., peptides versus lipids. Future experiments
are in progress to test the hypothesis that restricted expression
of MHC class I on DP thymocytes may lead to the develop-
ment of MHC class I–specific NK-type T cells.JEM VOL. 202, July 18, 2005 247
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MATERIALS AND METHODS
Mice. CD1d KO mice were bred for more than 14 generations onto either
NOD or C57BL/6 background in our laboratory. C57BL/6 mice and TCR
C  KO mice in the C57BL/6 background were purchased from Jackson
ImmunoResearch Laboratories. C57BL/6.E -CD1d mice expressing a
CD1d1 transgene driven by the MHC II E  promoter in a CD1d KO
background were previously described (27). To generate pLck-CD1d Tg
mice, we replaced the E  promoter in the previously described E -CD1d
construct with the proximal Lck promoter (29) excised (NotI and BamHI)
from the p1017 transgenic expression cassette (provided by Nigel Killeen,
University of California, San Francisco), as described in Fig. 1 A. This con-
struct contains exons, introns, and poly-adenylation sequence for optimal
expression. The linearized (SpeI and XhoI) construct was injected into fer-
tilized C57BL/6 oocytes and into fertilized NOD oocytes, and the injected
oocytes were implanted into pseudopregnant CD-1 (VAF ) outbred fe-
males. Transgenic mice were screened using PCR (forward primer: 5 -
TCCTGTGAACTTGGTGCTTGAG-3 ; reverse primer: 5 -CCAAAAT-
GATGAGACAGCACAAC-3 ) and were bred to C57BL/6.CD1d KO or
NOD.CD1d KO to obtain pLck-CD1d mice expressing the pLck-CD1d
transgene in the C57BL/6.CD1d KO (n   2) or to NOD.CD1d KO (n  
3) background, respectively. Because the NOD strain has a partial, recessive
defect in NKT cell development (42), the NOD.pLck-CD1d mice were fur-
ther crossed with C57BL/6.CD1d KO mice to generate NODxC57BL/6
F1.pLck-CD1d mice. All mice were housed in a specific pathogen-free facil-
ity at the University of Chicago according to the guidelines of the institu-
tional Animal Care and Use Committee.
Flow cytometry. Fluorochrome-conjugated mAbs anti-CD1d, CD3 ,
CD4, CD8 , CD11c, CD11b, CD24 (HSA), CD44, CD45, CD62L,
CD69, CD94, CD122, DX5, Gr-1, Ly49A, Ly49C/I, Ly49G2, NKG2A/
C/E, NK1.1, TCR V 2, V 6, V 7, and V 8.1 8.2, were purchased
from BD Biosciences. Anti-F4/80, B220, NKG2D mAbs, and streptavidin
conjugated with allophycocyanin or R-phycoerythrin were purchased from
eBioscience. Anti-I-Ab mAb (clone Y3P) was conjugated to FITC in our
laboratory. CD1d tetramers loaded with  -GalCer were prepared and used
in staining as described previously (43). BrdU staining of cells extracted
from mice (after one i.p. injection of 1 mg BrdU) was done according to
manufacturer’s instructions in BrdU Flow Kits (BD Biosciences). Flow
cytometry analysis was performed on a four-color FACSCalibur with
CELLQuest software (BD Biosciences).
Frozen section immunohistochemistry. Thymi were harvested, rinsed
with PBS, embedded in OCT freezing medium (Tissue-Tek, Sakura
Finetek), frozen in a mixture of 2-methylbutane (Sigma-Aldrich) and dry
ice, and stored at –20 C. Thymic sections were cut with a cryostat (10  m),
mounted on glass slides (Fisher Scientific International), dried, fixed with
acetone (Sigma-Aldrich), and covered with glass coverslips (Fisher Scientific
International). Thymic sections were first stained with a  5  g/ml of a
mixture of three purified rat anti-CD1d mAbs (clones 19G11, 17F5, and
16G9 in 1:1:1 ratio) developed in our laboratory. Biotinylated goat anti–rat
IgG, streptavidin-Texas red, and FITC-conjugated Y3P anti–I-Ab antibod-
ies were used in sequential order with washes in between. Fluorescence im-
ages were acquired with an Axiovert 200 microscope (Carl Zeiss MicroIm-
aging, Inc.) and processed with OpenLab (Improvision Inc.) and Adobe
Photoshop (Adobe Systems Inc.) software.
NKT cell purification and stimulation. Single-cell suspension of sple-
nocytes was first enriched by depleting B220  cells using B220-conjugated
magnetic microbeads with AutoMACS (Miltenyi Biotec) according to the
manufacturer’s instructions. CD1d- -GalCer tetramer NK1.1  cells were
then sorted with FACSAria (BD Biosciences), and cultured with DCs in
ER 10% medium, a 1:1 mixture of Eagle’s Ham’s amino acid and RPMI
1640 (Biofluids) enriched with 10% heat-inactivated FCS, glutamine, anti-
biotics, and 5   10 5 M of 2-mercaptoethanol. The DCs were prepared
from cultured BM in ER10% medium supplemented with mouse GM-CSF
(Biosource International) at 2 ng/ml for 6 d and pulsed with  -GalCer (100
ng/ml) overnight before washing and culture at 105 per well with titrated
numbers of NKT cells in 96 flat-bottom microwell plates (Corning Costar
Corporation). Stimulation assays were incubated for 48 h before assaying
IL-4 and IFN-  release with OptEIA ELISA sets (BD Biosciences) accord-
ing to manufacturer’s instructions. For in vivo experiments, mice were in-
jected i.v. with 5   105  -GalCer-pulsed DCs in PBS. The spleen fragment
assay measuring IL-4 release in vitro after 1.25  g anti-CD3  injection in
vivo was performed as described previously (24).
Radiation BM chimeras. C57BL/6.CD1d  KO mice were irradiated
(900 rad) 2 h before BM reconstitution. BM cells were harvested from
mouse femurs and depleted of T cells with FITC-conjugated anti-CD3 
mAb and anti-FITC magnetic microbeads on AutoMACS (Miltenyi Bio-
tec). BM cells from various donor combinations were mixed in a 1:1 ratio,
and a dose of 107 mixed BM cells was injected i.v. Chimeras were analyzed
6–8 wk after injection.
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